Axogen Inc vs Enovix Corporation — how do they compare? Axogen Inc trades at $49.23 (market cap $2.61B), while Enovix Corporation trades at $4.77 (market cap $1.06B). The key difference: Axogen Inc is far larger — about 2.5× Enovix Corporation's market cap, and Axogen Inc is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| AXGN | ENVX | |
|---|---|---|
Market Cap | $2.61B | $1.06B |
Sector | Technology | Technology |
52-Week High | $48.48 | $13.19 |
52-Week Low | $14.16 | $3.68 |
Enterprise Value | $2.52B | $1.07B |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $49.10, up 1.82% with strong technical momentum and bullish analyst sentiment. The stock shows robust revenue growth (23.1% in Q2 2026) and raised full-year guidance to $279 million, though profitability remains negative with a -13.36% net margin. Technical indicators show overbought RSI levels but strong moving average support, while institutional ownership and analyst consensus (84% buy ratings) signal confidence in the company's nerve care platform expansion.
The outlook remains positive given strong revenue momentum and regulatory advantages, but investors face execution risks from persistent losses and high valuation multiples. Upside potential exists toward the $54.33 consensus target if margin improvements materialize, though volatility may persist near current resistance levels.
ENVX is trading at $4.825, up 3.99% with strong analyst support (75% buy ratings) and a $12.38 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics, with recent earnings beats and strategic leadership appointments driving optimism. Revenue growth remains modest at $31.82M for 2025, but significant cash burn and negative margins highlight execution risks as the company scales battery production.
The outlook balances high growth potential in advanced battery technology against substantial financial losses. Investment opportunity lies in market leadership in silicon-anode batteries and recent operational improvements, while risks include persistent cash burn and competitive pressures in the evolving energy storage sector.
Trailing returns across standard periods
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →